| Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer (NCT00692900) | University of Pittsburgh | 2008-12-01 |
| Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers (NCT00803569) | Ludwig Institute for Cancer Research | 2008-11-14 |
| Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma (NCT00768144) | Dana-Farber Cancer Institute | 2008-09-01 |
| A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT00753480) | Genentech, Inc. | 2008-09-01 |
| Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT00801320) | Beth Israel Deaconess Medical Center | 2008-09-01 |
| Study of Ramucirumab in Ovarian Cancer (NCT00721162) | Eli Lilly and Company | 2008-08-01 |
| Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer (NCT00905658) | Centre Oscar Lambret | 2008-06-01 |
| Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod (NCT00799110) | Beth Israel Deaconess Medical Center | 2008-05-01 |
| Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00634894) | M.D. Anderson Cancer Center | 2008-03-01 |
| Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer (NCT00652899) | Masonic Cancer Center, University of Minnesota | 2008-03-01 |
| A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. (NCT00637390) | University of Michigan Rogel Cancer Center | 2008-03-01 |
| Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (NCT00569673) | Gynecologic Oncology Group | 2008-03-01 |
| Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00616941) | Ludwig Institute for Cancer Research | 2008-03-01 |
| Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin (NCT00652119) | Massachusetts General Hospital | 2008-02-01 |
| AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00574951) | Gynecologic Oncology Group | 2007-12-01 |
| Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) (NCT00562640) | Memorial Sloan Kettering Cancer Center | 2007-10-16 |
| Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer (NCT00702299) | University of Arizona | 2007-09-01 |
| A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients (NCT00526617) | AbbVie | 2007-08-01 |
| PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer (NCT00672295) | AA Secord | 2007-08-01 |
| Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors (NCT00520013) | Dana-Farber Cancer Institute | 2007-08-01 |
| Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer (NCT00479817) | Amgen | 2007-07-05 |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission (NCT00522301) | Memorial Sloan Kettering Cancer Center | 2007-07-01 |
| Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00748527) | Cancer Research UK | 2007-07-01 |
| Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00459290) | Gynecologic Oncology Group | 2007-05-01 |
| Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00536523) | University of Minnesota | 2007-04-01 |
| Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma (NCT00504257) | H. Lee Moffitt Cancer Center and Research Institute | 2007-03-01 |
| Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00429793) | National Cancer Institute (NCI) | 2007-02-01 |
| A Study of Chemotherapy Treatment for Patients With Ovarian Cancer (NCT00428610) | Eli Lilly and Company | 2007-02-01 |
| Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer (NCT00381888) | Masonic Cancer Center, University of Minnesota | 2007-01-01 |
| VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT00436501) | National Cancer Institute (NCI) | 2007-01-01 |
| Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer (NCT00436215) | National Cancer Institute (NCI) | 2006-12-12 |
| Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT00408070) | UConn Health | 2006-10-01 |
| ChemoFx® PRO - A Post-Market Data Collection Study (NCT00669422) | Precision Therapeutics | 2006-10-01 |
| OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (NCT00382811) | MEI Pharma, Inc. | 2006-10-01 |
| Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (NCT02349958) | Bay Area Gynecology Oncology | 2006-09-01 |
| Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma (NCT00390234) | National Cancer Institute (NCI) | 2006-09-01 |
| Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma (NCT00418093) | Dana-Farber Cancer Institute | 2006-09-01 |
| Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT00588237) | Memorial Sloan Kettering Cancer Center | 2006-08-01 |
| Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers (NCT00343044) | Benaroya Research Institute | 2006-06-01 |
| Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (NCT00303888) | Yale University | 2006-05-01 |
| Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy (NCT00466960) | University of Washington | 2006-05-01 |
| Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT00373217) | Craig L Slingluff, Jr | 2006-04-13 |
| Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer (NCT00322881) | Dana-Farber Cancer Institute | 2006-04-01 |
| Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer (NCT00334893) | National Cancer Institute (NCI) | 2006-04-01 |
| Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin (NCT00369954) | Gynecologic Oncology Group | 2006-04-01 |
| Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00897039) | Southeastern Gynecologic Oncology | 2006-03-01 |
| A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer (NCT00281632) | GlaxoSmithKline | 2006-03-01 |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer (NCT00601406) | The Christie NHS Foundation Trust | 2006-03-01 |
| Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire (NCT00517621) | ARCAGY/ GINECO GROUP | 2006-02-01 |
| Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer (NCT00182767) | National Cancer Institute (NCI) | 2006-01-01 |
| Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer (NCT00354601) | Wake Forest University Health Sciences | 2006-01-01 |
| Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma (NCT00582205) | University of Oklahoma | 2006-01-01 |
| Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers (NCT00086567) | National Cancer Institute (NCI) | 2005-12-12 |
| Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer (NCT00262990) | Novartis Pharmaceuticals | 2005-11-01 |
| Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT00267696) | Ohio State University Comprehensive Cancer Center | 2005-11-01 |
| Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer (NCT00466986) | Southeastern Gynecologic Oncology | 2005-11-01 |
| Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass (NCT00238342) | Gynecologic Oncology Group | 2005-10-01 |
| AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00275028) | National Cancer Institute (NCI) | 2005-10-01 |
| Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT00331422) | Masonic Cancer Center, University of Minnesota | 2005-10-01 |
| Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer (NCT00263822) | European Organisation for Research and Treatment of Cancer - EORTC | 2005-09-01 |
| Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer (NCT00230542) | Dana-Farber Cancer Institute | 2005-09-01 |
| Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients (NCT00268918) | Dana-Farber Cancer Institute | 2005-09-01 |
| Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer (NCT00499512) | M.D. Anderson Cancer Center | 2005-08-10 |
| Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients (NCT00478452) | University of Pennsylvania | 2005-08-01 |
| A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment (NCT00421889) | Valerio Therapeutics | 2005-08-01 |
| Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine (NCT00293293) | Masonic Cancer Center, University of Minnesota | 2005-05-01 |
| Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer (NCT00357448) | University of Washington | 2005-04-01 |
| Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT00126542) | National Cancer Institute (NCI) | 2005-04-01 |
| Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (NCT00189553) | ARCAGY/ GINECO GROUP | 2005-04-01 |
| Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer (NCT00295945) | University of California, San Francisco | 2005-03-01 |
| A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT00096993) | Genentech, Inc. | 2005-01-01 |
| Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT00112957) | Ludwig Institute for Cancer Research | 2004-12-01 |
| Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (NCT00138242) | Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center | 2004-12-01 |
| GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer (NCT00157573) | Massachusetts General Hospital | 2004-12-01 |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00317772) | M.D. Anderson Cancer Center | 2004-09-02 |
| Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT00287859) | Masonic Cancer Center, University of Minnesota | 2004-08-01 |
| Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00091377) | MEI Pharma, Inc. | 2004-08-01 |
| Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00288275) | Precision Therapeutics | 2004-07-01 |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00079430) | National Cancer Institute (NCI) | 2004-06-01 |
| Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer (NCT00217529) | Fred Hutchinson Cancer Center | 2004-06-01 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer (NCT00087191) | National Cancer Institute (NCI) | 2004-05-01 |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) (NCT00085358) | National Cancer Institute (NCI) | 2004-05-01 |
| Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse (NCT00189566) | ARCAGY/ GINECO GROUP | 2004-04-01 |
| Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer (NCT00245050) | Case Comprehensive Cancer Center | 2004-04-01 |
| Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer (NCT00287885) | Masonic Cancer Center, University of Minnesota | 2004-03-01 |
| Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00098878) | NHS Greater Glasgow and Clyde | 2004-03-01 |
| UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00072267) | University Health Network, Toronto | 2004-01-01 |
| Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00538031) | City of Hope Medical Center | 2003-12-22 |
| Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT00075712) | Royal College of Obstetricians and Gynecologists | 2003-09-01 |
| Letrozole in Patients With Ovarian Tumors (NCT00505661) | M.D. Anderson Cancer Center | 2003-09-01 |
| Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors (NCT00066651) | National Cancer Institute (NCI) | 2003-07-01 |
| Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00066729) | Ludwig Institute for Cancer Research | 2003-06-23 |
| Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma (NCT00653328) | Vanderbilt-Ingram Cancer Center | 2003-05-01 |
| S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00053833) | SWOG Cancer Research Network | 2003-04-01 |
| PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer (NCT00059618) | M.D. Anderson Cancer Center | 2003-04-01 |
| Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma (NCT00226915) | Japanese Gynecologic Oncology Group | 2003-04-01 |
| Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma (NCT00059787) | National Cancer Institute (NCI) | 2003-04-01 |
| Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer (NCT00501644) | M.D. Anderson Cancer Center | 2003-01-01 |
| Depression Treatment and Screening in Ovarian Cancer Patients (NCT00515372) | M.D. Anderson Cancer Center | 2002-12-20 |
| Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer (NCT00061308) | GlaxoSmithKline | 2002-12-01 |